Driehuis, Else et al. published their research in Proceedings of the National Academy of Sciences of the United States of America in 2019 | CAS: 219580-11-7

1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea (cas: 219580-11-7) belongs to pyrimidine derivatives. Heterocyclic compounds bearing the pyrimidine core are of tremendous interest as they constitute an important class of natural and synthetic compounds exhibiting diverse useful biological activities that hold attractive potential for clinical translation as therapeutic agents in alleviation of a myriad of diseases. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.SDS of cas: 219580-11-7

Pancreatic cancer organoids recapitulate disease and allow personalized drug screening was written by Driehuis, Else;van Hoeck, Arne;Moore, Kat;Kolders, Sigrid;Francies, Hayley E.;Gulersonmez, M. Can;Stigter, Edwin C. A.;Burgering, Boudewijn;Geurts, Veerle;Gracanin, Ana;Bounova, Gergana;Morsink, Folkert H.;Vries, Robert;Boj, Sylvia;van Es, Johan;Offerhaus, G. Johan A.;Kranenburg, Onno;Garnett, Mathew J.;Wessels, Lodewyk;Cuppen, Edwin;Brosens, Lodewijk A. A.;Clevers, Hans. And the article was included in Proceedings of the National Academy of Sciences of the United States of America in 2019.SDS of cas: 219580-11-7 The following contents are mentioned in the article:

We report the derivation of 30 patient-derived organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histol. and contain genetic alterations typical of pancreatic cancer. In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not exploited in the clinic, and underscores the importance of personalized approaches for effective cancer treatment. The PRMT5 inhibitor EZP015556, shown to target MTAP (a gene commonly lost in pancreatic cancer)-neg. tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP-pos. tumors. Taken together, the work presented here provides a platform to identify novel therapeutics to target pancreatic tumor cells using PDOs. This study involved multiple reactions and reactants, such as 1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea (cas: 219580-11-7SDS of cas: 219580-11-7).

1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea (cas: 219580-11-7) belongs to pyrimidine derivatives. Heterocyclic compounds bearing the pyrimidine core are of tremendous interest as they constitute an important class of natural and synthetic compounds exhibiting diverse useful biological activities that hold attractive potential for clinical translation as therapeutic agents in alleviation of a myriad of diseases. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.SDS of cas: 219580-11-7

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia